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ABSTRACT
Breast cancer remains one of the leading causes of cancer mortality among 
women. It has been proved that the onset of cancer depends on a very small pool of 
tumor cells with a phenotype similar to that of normal adult stem cells. Cancer stem 
cells (CSC) possess self-renewal and multilineage differentiation potential as well 
as a robust ability to sustain tumorigenesis. Evidence suggests that CSCs contribute 
to chemotherapy resistance and to survival under hypoxic conditions. Interestingly, 
hypoxia in turn regulates self-renewal in CSCs and these effects may be primarily 
mediated by hypoxic inducible factors (HIFs). Recently, microRNAs (miRNAs) have 
emerged as critical players in the maintenance of pluripotency and self-renewal in 
normal and cancer stem cells. Here, we demonstrate that miR-24 is upregulated in 
breast CSCs and that its overexpression increases the number of mammospheres 
and the expression of stem cell markers. MiR-24 also induces apoptosis resistance 
through the regulation of BimL expression. Moreover, we identify a new miR-24 
target, FIH1, which promotes HIFα degradation: miR-24 increases under hypoxic 
conditions, causing downregulation of FIH1 and upregulation of HIF1α. In conclusion, 
miR-24 hampers chemotherapy-induced apoptosis in breast CSCs and increases cell 
resistance to hypoxic conditions through an FIH1−HIFα pathway.
INTRODUCTION
Despite many novel therapeutic approaches, breast 
cancer remains one of the leading causes of cancer 
mortality among women. It has recently been proved 
that the onset of cancer depends on a very small pool of 
tumor cells with a phenotype similar to that of normal 
adult stem cells [1]. Cancer stem cells (CSCs) are rare, 
tumor-initiating cells that exhibit stem cell properties: 
capacity for self-renewal, pluripotency, high tumorigenic 
potential, and resistance to therapy [2]. CSCs have been 
isolated from most human solid tumor types, suggesting 
their central role in tumor development, progression, 
and recurrence [3]. The CSC pool is associated with 
aggressiveness and a negative prognosis in breast cancer 
patients and its presence has important implications in 
cancer treatment. Current anti-cancer therapy is effective 
for removing the tumor mass, but the effects are often 
transient, leading to relapses and metastatic disease. A 
possible explanation for the failure of anti-cancer therapies 
is that they fail to kill CSCs, and even therapies that cause 
complete tumor regression might spare enough CSCs to 
allow regrowth.
Moreover, CSCs have a great capacity to survive in 
hypoxic microenvironments. In a solid tumor, rapid growth 
and aberrant blood flow often generate areas of hypoxia 
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[4]. Hypoxic tumors have a more aggressive phenotype, 
showing more propensity to metastasize, poorer prognosis, 
and increased resistance to radiotherapy and chemotherapy 
[5]. The main regulators of the hypoxia signaling pathway 
are the HIF proteins. The stabilization of HIF proteins in 
hypoxic cancer cells promotes tumor progression through 
the regulation of the expression of players such as VEGF, 
glycolytic enzymes, glucose transporters, and proteins 
regulating mobility and metastasis [6, 7]. Furthermore, 
HIFs regulate signaling pathways that control stem 
cell properties, metabolic reprogramming, epithelial 
mesenchymal transition (EMT), metastasis and resistance 
to therapy [8].
Recently, microRNAs (miRNAs) have emerged as 
critical players in the maintenance of pluripotency, control 
of self-renewal, and cell fate [9–12]. Embryonic stem cells 
express specific patterns of miRNAs [13, 14], and specific 
miRNAs regulate and are regulated by key stem cell 
genes [15, 16]. Most miRNAs important for embryonic 
stem cell biology participate also in oncogenesis, mainly 
by promoting EMT [17, 18], metastasis [19] and survival 
in hypoxia.
An abundant miRNA that is highly conserved in 
different species is miR-24. It is clustered with two other 
miRNAs on chromosome 9 (cluster-1: miR-23b, miR-
27b, and miR-24-1) and on chromosome 19 (cluster-2: 
miR-23a, miR-27a, and miR-24-2). Recent evidence 
indicates that miR-24 is an oncomiR in several cancer 
formation processes, such as in breast carcinoma and 
glioma; however, it acts as a tumor suppressor in laryngeal 
carcinoma [20]. Similarly, the role of miR-24 in stemness 
is incongruous, since it can promoter either differentiation 
or stemness depending on the cell type [21–24]. Here, we 
show that miR-24 acts as a stress sensor in breast CSCs, 
interfering with chemotherapy-induced apoptosis and, 
more importantly, regulating CSC resistance to hypoxic 
conditions.
RESULTS
MiR-24 modulates the stemness properties of 
breast cancer cells
Microarray analysis has identified several miRNAs 
differently expressed in primary BCSCs compared to 
differentiated cells [25]. Among these, we found miR-24 
to be up-regulated in mammospheres. Microarray data 
were confirmed by qRT-PCR (Figure 1A). Suspension 
cultures of T47D, MCF-7, MDA-MB-231, and BT-549 
breast cancer cells were used to enrich for BCSCs. Some 
molecular characteristics, including expression of stem cell 
markers, were increased in suspension cultures compared 
to differentiated cells, as confirmed by Western blotting 
and qRT-PCR in T47D [25], MCF-7, MDA-MB-231 and 
BT-549 cells (Supplementary Figure S1A-S1B). MiR-24 
was upregulated in mammosphere populations originated 
from T47D, MCF-7, MDA-MB-231 and BT-549 cells, 
similarly to what was observed in primary BCSCs 
(Figure 1B).
To investigate the biological implication of miR-
24 upregulation in BCSCs, we modulated miR-24 levels 
in differentiated T47D, MCF-7 and MDA-MB-231 
cells (Supplementary Figure S1C) and then assessed 
their capacity to form mammospheres. Overexpression 
of miR-24 boosted the formation of mammospheres in 
breast cancer cell lines (Figure 1C) and in cultures from 
primary breast tumor cells (Figure 1D). In addition, miR-
24 overexpression led to the increase of several stemness 
genes, including Nanog, Oct-3/4, and Vimentin, and 
the reduction of E-cadherin, in T47D and MCF-7 cells 
(Figure 1E, 1F). Importantly, the expression of anti-miR-24 
induced the opposite effect (Supplementary Figure S2A-
S2D). These findings suggest that miR-24 contributes 
to the regulation of key pathways implicated in the 
maintenance of the stem cell phenotype in breast cancer.
Since the stem cell pool is correlated with a more 
aggressive phenotype, we evaluated whether the up-
regulation of miR-24 was associated with bad prognosis 
and survival. We used MIRUMIR [26] (http://www.
bioprofiling.de/GEO/MIRUMIR/mirumir.html), an online 
tool that provides an analysis of miRNAs as potential 
biomarkers, to predict survival in cancer patients. We 
found that high expression of miR-24 was associated with 
poor outcome in breast cancer. Interestingly, statistical 
significance was also reached in another two publically 
available datasets (nasopharingeal carcinoma and 
osteosarcoma), supporting an oncogenic role for miR-24 
(Supplementary Figure S3).
MiR-24 induces resistance to cisplatin
Chemoresistance plays a crucial role in breast 
cancer relapse and recurrence. This phenomenon is tightly 
linked to the characteristics of BCSCs that allow them 
further resistance to the treatment [27]. To confirm this 
observation, we compared apoptosis in T47D and MDA-
MB-231 mammosphere and adherent cell cultures after 
48h of cisplatin treatment. We found that BCSCs from 
T47D and MDA-MB-231 cells were more viable (data not 
shown) and exhibited a lower level of Caspase-3 activation 
after cisplatin treatment compared to differentiated cells 
(data not shown).
Cancer stem cells are more resistant than 
differentiated cells to cisplatin. In order to assess whether 
this property was in part mediated by the high levels of 
miR-24, we evaluated the effect of its overexpression on 
cells exposed to cisplatin. MiR-24 decreased the degree of 
apoptosis in breast cancer cells, as assessed by Caspase-3/7 
activity (Figure 2A, 2B, 2C), PARP, and Caspase-3 cleavage 
(Figure 2D, 2E). To further confirm the effect of miR-24 
as a chemotherapeutic protector, we transfected MDA-
MB-231 stem cells with an anti-miR-24. We found that 
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downregulation of miR-24 in cancer stem cells induced 
an increase of Caspase-3 activation and of PARP cleavage 
compared to anti-scrambled control (Figure 2F, 2G). 
Taken together, these results indicate that miR-24 induces 
enhanced resistance to apoptosis in BCSCs.
Downregulation of BimL is involved in miR-24-
mediated resistance to cisplatin
MiR-24 is known to bind to the 3’UTR of bimL, 
impairing translation of the mRNA [28]. BimL is an 
isoform generated by alternative splicing of bim, a member 
of the Bcl-2 family involved in the intrinsic apoptotic 
pathway. To confirm bimL as a target of miR-24 also in 
breast cancer cells, we transfected T47D cells with pre-
miR-24 for 48 h and then analyzed BimL levels by qRT-
PCR and Western blotting. Indeed, miR-24 downregulated 
bimL mRNA and protein levels (Figure 3A). Coherently, 
BimL protein expression was increased in T47D cells 
transfected with anti-miR-24 (Figure 3B). Furthermore, 
the expression of miR-24 was inversely correlated with 
BimL also in T47D mammosphere cultures (Figure 3C). 
To demonstrate the involvement of BimL in miR-24-
induced cisplatin resistance, we transfected T47D cells 
with miR-24 or a scrambled control and then treated the 
cells with cisplatin for 48 h. As anticipated, increased 
expression of BimL was found in control cells but not in 
those overexpressing miR-24 (Figure 3D). To prove the 
direct links between miR-24, downregulation of BimL, 
and resistance to apoptosis, we carried out a rescue 
experiment by transfecting T47D cells with pre-miR-24 
and a BimL cDNA lacking the 3’UTR. We found that 
overexpression of miR-24-resistant BimL had an effect on 
miR-24-mediated resistance to cisplatin (Figure 3E) and 
Figure 1: MiR-24 expression in BCSCs. A. miR-24 expression analyzed by qRT-PCR in primary breast cancer cells cultured in 
suspension (stem cell enriched) or adherent (differentiated) conditions. B. qRT-PCR levels of miR-24 in T47D, MCF-7, MDA-MB-231, 
and BT-549 breast cancer and in differentiated cells. C. T47D, MCF-7, and BT-549 cells were transfected with miR-24 or a scrambled 
oligonucleotide, grown as mammospheres, and counted after 6 days. D. Primary cells were transfected with miR-24 or scambled 
oligonucleotide, grown as mammospheres and counted after 6 days. E-F. Western blot showing that miR-24 overexpression in T47D and 
MCF-7 cells determines an upregulation of the stem markers Nanog, Oct-3/4, and Vimentin, and a downregulation of E-cadherin. In B, C, 
D, data are mean values ± SD of three independent experiments. Significance was calculated using Student’s t-test.*, p<0.05; **, p<0.01. 
Western blots are from representative experiments.
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reverted miR-24’s effects also on mammosphere formation 
(Figure 3F). Similar results were obtained in the MDA-
MB-231 cell line (Supplementary Figure S2E-S2H).
Expression of miR-24 in hypoxic conditions
Stem cells reside in specialized microenvironments 
or niches that regulate their function. In vitro studies 
employing hypoxic culture conditions have revealed 
strong regulatory links between O2 availability and stem/
precursor cell functions [29]. It has been reported that 
miR-24 has a HIF binding site on its promoter region 
[30]. Therefore, we assessed if miR-24 expression was 
induced under hypoxic conditions, thus contributing to 
stem cell survival. To this end, expression of miR-24 was 
analyzed in MCF-7, MDA-MB-231 and BT-549 cells 
cultured in an incubator with 1% O2 for 6h, and then 
miR-24 expression was analyzed by qRT-PCR. Indeed, 
miR-24 was induced by hypoxia in all breast cancer cells 
tested (Figure 4A). Moreover, MCF-7, MDA-MB-231, 
BT-549 and T47D cells transfected with miR-24 formed 
more mammospheres than control cells when cultured 
under hypoxic conditions (Figure 4B). Of note, we 
found that expression of Nanog and Oct-3/4 stemness 
genes was increased upon hypoxia, in particular in cells 
overexpressing miR-24 (Figure 4C, D). Interestingly, we 
also found that the level of BimL was decreased during 
hypoxia, and that this was more evident upon miR-24 
transfection (Figure 4E).
Analysis of genes involved in hypoxia and EMT 
pathways
Hypoxia regulates stem cell function through the 
direct activation of specific HIF target genes. HIF1α 
plays a key role in many crucial aspects of breast cancer 
biology, including stem cell maintenance, metabolic 
reprogramming, EMT, metastasis, and resistance to 
therapy. Therefore, we investigated miR-24’s effect on 
the expression of HIF1α. To this end, MCF-7, MDA-
Figure 2: MiR-24 regulates the response to cisplatin in breast cancer cells. A, B, C. miR-24 transfection increased cisplatin 
resistance in T47D, BT-549, and MDA-MB-231 cells as assessed by Caspase-3/7 assay and D, E. by Western blot for cleaved PARP 
and Caspase-3. F, G. Anti-miR-24 transfection increased sensibility to cisplatin in MDA-MB-231 cancer stem cells. Western blots show 
representative experiments. Data are mean values ± SD of three independent experiments. In A, B, and F, significance was calculated using 
Student’s t-test.*, p<0.05; **, p<0.01.
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MB-231, BT-549 and T47D cells were transfected with 
either a scrambled oligonucleotide or a pre-miR-24 for 
24h and then cultured under hypoxic conditions for 6h. 
We found that miR-24 upregulated HIF1α expression 
levels (Figure 5A). Furthermore, expression of two direct 
HIF1α targets, Snail and VEGFA, were increased (Figure 
5B, 5C). These findings suggest that miR-24 induces an 
adaptive response to the toxic stimulus (i.e., low oxygen) 
by inducing expression of hypoxia inducible factors.
MiR-24 downregulates FIH1
We next investigated the mechanism of miR-
24-mediated HIF1α protein stabilization. We found 
FIH1, an asparaginyl β-hydroxylase that promotes 
transcriptional repression of HIFs, among the potential 
miR-24 targets predicted by bioinformatics programs 
(Figure 6A). To verify whether miR-24 recognizes the 
3’UTR of FIH1, this region was cloned downstream 
of a luciferase reporter gene. FIH1 3′UTR luciferase 
reporter activity was significantly repressed upon 
the addition of miR-24, while it was not affected by 
overexpression of miR-24 in the presence of a mutant 
construct in which the seed sequence was cloned back 
to front (Figure 6A). Real time-PCR and Western 
blotting of cells overexpressing miR-24 confirmed the 
decrease of FIH1 at mRNA (Figure 6B) and protein 
(Figure 6C, 6D) levels. Coherently, transfection of an 
anti-miR-24 oligonucleotide increased FIH1 expression 
(Figure 6C, 6D). Of note, hypoxia decreased FIH1 
protein levels, an effect enhanced by overexpression of 
miR-24 (Figure 6E, 6F).
Figure 3: MiR-24 mediates cisplatin resistance by down-modulating BimL. MiR-24 downregulates BimL at mRNA and 
protein levels, as assessed by qRT-PCR and Western blotting in T47D cells A. On the contrary, anti-miR-24 increased in BimL expression 
B. Endogenous levels of BimL are higher in differentiated T47D cells compared to stem cells C. MiR-24 transfection reduced cisplatin’s 
effect on BimL levels D. Rescue experiment with the concomitant transfection of miR-24 and BimL cDNA lacking the 3’UTR, indicated that 
cisplatin resistance (assessed with a Caspase-3/7 assay) was in part reverted E. BimL also reverted the effect of miR-24 on mammosphere 
formation F. In A, B, E and F, data are mean values ± SD from three independent experiments. In A, B and E, significance was calculated 
using Student’s t-test.*, p<0.05; **, p<0.01; ***, p<0,001. In F, significance was calculated with ANOVA and Bonifaci correction.***, 
p<0,001. Western blotting analyses are from representative experiments.
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Overexpression of FIH1 reverts miR-24-
mediated effects
To investigate whether miR-24-mediated 
downregulation of FIH1 was really responsible for the 
stemness features observed under hypoxia, we performed 
a rescue experiment. To this end, we transfected MDA-
MB-231 and BT-549 breast cancer cells with pre-miR-24 
and a FIH1 cDNA lacking the 3′UTR, and analyzed 
the effect on mammosphere formation, migration and 
HIF1α expression. Interestingly, miR-24’s effect on 
mammosphere formation was abolished by overexpression 
of FIH1 in both cancer cell lines (Figure 7A, 7B). In 
addition, under hypoxic conditions miR-24 significantly 
increased migration of MDA-MB-231 and BT-459 cells. 
In contrast, overexpression of FIH1 cDNA partially 
reverted cell motility (Figure 7C, 7D). Finally, we also 
verified that FIH1 overexpression was able to revert the 
effect of miR-24 on Nanog and Oct-3/4 expression in BT-
549 (Figure 8A, 8B) and MDA-MB-231 (Supplementary 
Figure S4A, S4B) cells, and that it reverted the action of 
miR-24 on HIF1α upregulation as well as of its targets 
Snail and VEGF (Figure 8C, 8D, 8E, Supplementary 
Figure S4C, S4D, S4E).
DISCUSSION
Many studies strongly support the concept that 
breast tumors originate from mammary stem cells that have 
become mutated during self-renewal or differentiation 
processes [31]. Poorly differentiated cancers display 
higher CSC content than well-differentiated tumors 
[32], in agreement with the concept that the proportion 
of CSCs reflects tumor malignancy [33]. CSCs may be 
responsible for poor prognosis, since they are resistant to 
current forms of therapy and, therefore, are responsible for 
the recurrence of the disease [34–36]. Therefore, further 
understanding of the molecular mechanisms underlying 
CSC maintenance is needed if we are to develop therapies 
that can eradicate breast cancer [37].
Recently, miRNAs have been found to be critical 
for various cellular processes, acting as major post-
transcriptional regulators [38]. By their ability to 
target hundreds of mRNAs, they can induce rapid and 
Figure 4: MiR-24 levels are regulated by hypoxia. A. MiR-24 levels, analyzed by qRT-PCR, were increased under hypoxic 
conditions in MDA-MB-231, BT-549, MCF-7 and T47D cells. B. MiR-24 overexpression upregulates mammosphere formation under 
hypoxia. C, D. MiR-24 up-regulates Nanog and Oct-3/4 expression in MDA-MB-231, BT-549 and T47D cells, as assessed by real time 
PCR. E. MiR-24 down-regulates BimL RNA in normoxic and hypoxic conditions. In A, B, C and D, data are mean values ± SD from two 
independent experiments. Significance was calculated using Student’s t-test.*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0,001.
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simultaneous switches in cell fate and genome expression. 
miRNAs have been frequently found deregulated in 
different human cancers, acting either as oncogenes or 
tumor suppressors [39–41]. MiRNAs may regulate the 
stemness of embryonic stem cells, and at the same time 
may act as essential regulators of ESC differentiation [42, 
43]. More interestingly, some miRNAs have been reported 
to regulate CSC phenotype, controlling self-renewal and 
differentiation [44].
The threat posed by CSCs derives from their 
unique properties: they have a slow rate of division 
compared to differentiated cells (i.e., they are quiescent); 
they overexpress drug transporters and DNA repair 
proteins that confer resistance to chemotherapeutics; and 
they have the ability to survive under adverse conditions, 
such as a hypoxic microenvironment. Areas of hypoxia 
are common in cancers in which the expanding 
tumor causes poor oxygen diffusion and chaotic 
vascularization. Moreover, hypoxia may contribute 
to CSC maintenance by promoting a pro-survival 
response and altering cellular behavior through multiple 
mechanisms affecting metabolism, angiogenesis, and 
invasion/migration [45]. Indeed, hypoxia increases self-
renewal capacity as well as induction of essential stem 
cell factors, such as Oct-3/4, Nanog, and c-Myc [6]. 
Moreover, it promotes an immature phenotype in solid 
tumors such as human neuroblastoma, breast cancer [8, 
46], and glioma [47].
The effects of hypoxia on CSCs seem to be primarily 
mediated by hypoxia inducible factors. HIF1, consisting 
of HIF1α and HIF1β subunits [48], is a key mediator 
of the cell response to hypoxia, and its high expression 
correlates with poor prognosis in various tumor types [4]. 
The transcriptional activity of HIF1 residing in the HIF1α 
subunit is partly controlled by asparaginyl hydroxylation 
by factor-inhibiting HIF hydroxylase 1(FIH1) [49]. FIH1 
was originally found to be a negative regulator of HIF1 
and was later shown to be an asparaginyl hydroxylase 
capable of hydroxylating N803 in the C-terminal 
activation domain of human HIF1 [50–52]. Recent 
studies have demonstrated that FIH1 may be regulated by 
microRNAs [53, 54].
Figure 5: MiR-24 regulates HIF1α levels and hypoxia pathways. A. MiR-24 modulated HIF1α expression during hypoxia at 
the protein level in MCF-7, MDA-MB-231, BT549 and T47D cells. B, C. Real time PCR showing induction of Snail and VEGF mRNAs 
by miR-24 in hypoxic conditions. In B and C, data are mean values ± SD from two independent experiments. Significance was calculated 
using Student’s t-test.*, p<0.05;**, p<0.01; Western blots are representative experiments.
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Figure 6: MiR-24 regulates hypoxia pathways by targeting FIH1. Predicted alignment between the miR-24 sequence and the 3′UTR of 
FIH1. Luciferase reporter assays show that reporter activity was inhibited in MCF-7 cells only in the presence of wild type and not mutated 3′UTR 
FIH1 A. miR-24 transfection downregulated FIH1 mRNA and protein levels, as assessed by qRT-PCR B. and Western blotting C, D. whereas 
transfection of anti-miR-24 upregulated FIH1 levels in MCF-7 and BT-549 cells C, D. Western blot showing that FIH1 is downregulated during 
hypoxia and upon miR-24 expression in MCF-7 and BT-549 cells E, F. Western blots are representative experiments. In A and B, data are mean 
values ± SD from two independent experiments. Significance was calculated using Student’s t-test. **, p<0.01; ***, p<0.001.
Figure 7: FIH1 rescues the effects of miR-24 on mammosphere formation and cell migration during hypoxia. FIH1 cDNA 
transfection in MDA-MB-231 and BT-459 cells reverted the effect of miR-24 on A. mammosphere formation and C. migration. B, D. Western 
blot analysis of HIF1α and FIH1 expression in the rescue experiment in MDA-MB-231 and BT-549 cells upon hypoxia. E. Western blot 
analysis of BimL expression in the rescue experiment in MDA-MB-231 cells upon hypoxia. In A and C, data are mean values ± SD from 
two independent experiments. Significance was calculated using Student’s t-test.*, p<0.05; **, p<0.01; ***, p<0.001.
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In high-grade gliomas, a genetic alteration 
characterized by deletion of chromosome 10q23–q26 
encompassing the FIH1 locus at 10q24 has been described 
[55]. FIH-1 loss of function may contribute to increased 
HIF1-mediated transactivation of downstream target 
genes, such as VEGF in gliomas and other human cancers 
[56], thus conferring a growth advantage to stem cells 
under hypoxic conditions.
In the present study, we identify miR-24 as 
an important player in the control of breast CSCs 
maintenance, at least in part through the regulation 
of FIH1 and Bim levels. We provide evidence that 
miR-24 is upregulated in the stem cell population of 
primary tumors and breast cancer cell lines compared to 
differentiated cells. Moreover, miR-24 was upregulated 
in hypoxic conditions, and overexpression of miR-24 
increased mammospheres formation in normoxic, as 
well as in hypoxic conditions. MiR-24 increased HIF1α 
protein, in part by directly targeting FIH1. Moreover, 
miR-24 increased two common HIF target proteins, Snail 
and VEGF, which are involved in conferring a growth 
advantage to cancer cells under hypoxic conditions.
MiR-24 plays an important role in various types 
of cancer. Indeed, expression of the miR-23a~27a~24-2 
cluster is upregulated in acute lymphoblastic leukemia 
[57], acute myeloid leukemia, chronic lymphocytic 
leukemia [58], breast cancer [59], gastric cancer [60], and 
hepatocellular carcinoma cells [61]. Moreover, antisense 
inhibition of miR-24 attenuated A549 cell growth [62]. 
Recently, overexpression of miR-24 was shown to 
promote cell proliferation and inhibit apoptosis in MDA-
MB-435 and MDA-MB-468 mammary adenocarcinoma 
cell lines, with p27Kip1 identified as the direct miR-24-3p 
target mediating these effects [59]. Other reported targets 
of miR-24 include proapoptotic (FAF-1, Caspase-9, Bim, 
and Apaf-1) and cell cycle proteins [28, 63–65]; miR-24 
was also shown to regulate XIAP, reducing the threshold 
for apoptosis in cancer cells [66].
Besides modulating survival when oxygen is scarce, 
miR-24 may affect stem cell behavior by hindering 
Figure 8: FIH1 reverts the effects of miR-24 on stem markers and on HIF1α in BT-549 cells during hypoxia. FIH1 cDNA 
transfection in BT-549 cells abolished the effect of miR-24 on Nanog and Oct-3/4 expression A, B. FIH1 also reverted the effect of the 
miR-24 on HIF1α E. and its targets Snail and VEGF C, D. In A, B, C, and D data are mean values ± SD from two independent experiments. 
Significance was calculated using Student’s t-test.*, p<0.05.
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chemotherapy-induced apoptosis. Indeed, we demonstrate 
that overexpression of miR-24 increases the resistance to 
cisplatin, and that this effect is mediated by inhibition of 
the pro-apoptotic protein BimL, which has previously 
been described as a miR-24 target in cardiomyocytes [28]. 
We also show that differentiated cells overexpressing miR-
24 have an enhanced capacity to form mammospheres, 
and that overexpression of BimL inhibits this effect, 
suggesting that the regulation of apoptosis is involved in 
the stemness phenotype. It is well known that stem cells 
are more resistant to anoikis, namely cell death induced 
by detachment from the extracellular matrix. This may 
suggest that miR-24 protects stem cells from this kind 
of death, favoring their survival. Furthermore, miR-
24 has also been implicated in stem cell maintenance 
and resistance to therapy in other systems, for example 
it was found to be enriched in CD34+ HSPCs, where it 
played a role as a regulator of normal erythropoiesis 
via targeting of human activin receptor type 1, ALK4 
[67]. Some reports have described that miR-24 inhibits 
erythroid differentiation of K562 cells, erythroid colony 
formation, and maturation of human CD34+ hematopoietic 
progenitor cells. Pan et al. have shown that miR-24-3p 
overexpression inhibited autophagy induction and reduced 
cell viability with VP16–DDP treatment, by targeting the 
autophagy-related gene ATG4A in small lung cancer cells 
[68].
In summary, we report here for the first time 
that miR-24 regulates stem cell maintenance in 
breast cancer, contributing to the preservation of 
the stem cell compartment from stressful conditions 
such as chemotherapy or hypoxia. MiR-24 regulates 
apoptosis by targeting BimL, contributing to resistance 
to cisplatin. Moreover, by targeting Fih1, miR-24 
regulates HIF expression, conferring stem cells a 
growth advantage in hypoxic conditions (Figure 9). 
In conclusion, these findings suggest that inhibition 
of miR-24 might be a useful strategy for combating 
chemoresistance and survival of breast cancer cells in 
hypoxia.
Figure 9: Mechanism of action of miR-24 in breast cancer stem cells. Toxic stimuli induce expression of miR-24. MiR-24 
downregulates BimL (inducing resistance to chemotherapeutics) and FIH1 (inducing resistance under hypoxia).
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MATERIALS AND METHODS
Cell and mammosphere cultures
Differentiated cells from breast tumors of three 
patients (#1, #2, #3) and breast cancer stem cells (BCSCs) 
were obtained and used for microRNA array as previously 
described [25, 69]. T47D, BT-549, and MDA-MB-231 
cells were grown in RPMI 1640. MCF-7 cells were grown 
in DMEM. Media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
and 100 U/ml penicillin/streptomycin. T47D, BT549, 
MDA-MB-231, and MCF-7 cells were from ATCC (LG 
Standards, Milan Italy). All media and supplements were 
from Sigma Aldrich (Milan, Italy) unless stated otherwise.
For mammosphere culture, T47D, BT-549, MDA-
MB-231, and MCF-7cells were plated at a density of 
1,000 cells/ml in non-adherent conditions. Cells were 
grown in serum-free DMEM-F12 supplemented with B27 
(Life Technologies), 10 ng/ml EGF, 20 ng/ml β FGF (BD 
Biosciences, Milan, Italy), and 1X antibiotic-anti-mycotic 
(Life Technologies). After 5−7 days, mammospheres, 
which appeared as spheres of floating viable cells, 
were collected by gentle centrifugation (800 rpm) and 
dissociated with 0.25% trypsin for 5 min.
Transfection of cells and spheres
For transient transfection of miRNAs, cells at 50% 
confluence were transfected with either 100 nM pre-
miR-24, scrambled pre-miR-24, or anti-miR-24 (Ambion, 
Life Technologies) in Oligofectamine (Thermo Fisher 
Scientific). To overexpress BimL, cells were transfected 
with 3 µg BimLcDNA, a kind gift of Dr. Douglas Green 
(St. Jude Children’s Research Hospital, Memphis, TN, 
USA), in Lipofectamine 2000 (Thermo Fisher Scientific). 
To overexpress FIH-1, cells were transfected with 3 μg 
FIH1 cDNA (OriGene Technologies, Rockville, USA) in 
Lipofectamine 2000.
Protein isolation and western blotting
Cells were washed twice in ice-cold PBS, and lysed 
in JS buffer (50 mM HEPES, pH 7.5, containing 150 
mMNaCl, 1% glycerol, 1% Triton X100, 1.5mM MgCl2, 
5mM EGTA, 1 mM Na3VO4, and 1X protease inhibitor 
cocktail). Protein concentration was determined by the 
Bradford assay (BioRad, Milan, Italy) using bovine serum 
albumin as the standard, and equal amounts of proteins 
were resolved by SDS-PAGE (12.5% acrylamide). Gels 
were electroblotted onto nitrocellulose membranes (G&E 
Healthcare, Milan, Italy), which were then blocked 
for 1h with 5% non-fat dry milk in Tris-buffered saline 
(TBS) containing 0.1% Tween-20, and incubated at 
4°C overnight with a primary antibody. Detection 
was performed with peroxidase-conjugated secondary 
antibodies using the enhanced chemiluminescence system 
(Thermo, Euroclone, Milan, Italy). The primary antibodies 
used were: anti-Oct-3/4, anti-Nanog, anti-E-cadherin, 
anti-Vimentin (all from Santa Cruz Biotechnologies, MA, 
USA), anti-BimL, anti-PARP, anti-Caspase-3 (from Cell 
Signaling Technology, Milan, Italy), anti-human HIF1α 
(BD Biosciences, Milan, Italy), anti-FIH1(Abcam, MA, 
USA) and anti-βActin (Sigma Aldrich).
Mammosphere formation quantification
Mammospheres were resuspended in 0.5% agar 
(Bacto-Agar, Difco Laboratories, NSW, Australia) and 
layered onto 60 mm Petri dishes with a preformed 0.8% 
agar layer (BD Biosciences). Colonies were counted under 
an inverted microscope (Nikon, Milan, Italy) and then 
photographed.
RNA extraction and real-time PCR
Total RNAs (miRNA and mRNA) were extracted 
using Trizol (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. Reverse transcription of 
total miRNA was performed using miScript reverse 
Transcription Kit (Qiagen, Milan, Italy), for mRNA was 
used SuperScript® III Reverse Transcriptase (Thermo 
Fisher Scientific). Quantitative analysis of Nanog, Oct-
3/4, BimL, FIH1, VEGF, SNAIL, and Actin (as an internal 
reference), miR-24, and RNU6B (as an internal reference) 
was performed by RealTime PCR using specific primers 
(Qiagen), miScript SYBR Green PCR Kit (Qiagen), and 
iQTM SYBR Green Supermix (Bio-Rad), respectively.
Cell death and cell proliferation quantification
Cells were plated in 96-well plates in triplicate 
and incubated at 37°C in a 5% CO2 incubator. Cisplatin 
(Sigma Aldrich) was used for 48 h at 20 µg/ml. Apoptosis 
was analyzed with Caspase-Glo® 3/7 Assay Systems 
(Promega), according to the manufacturer’s protocol. 
Briefly, cells were incubated with medium supplemented 
with Caspase-3/7 reagent. Luminescence was measured 
following an incubation of 30 minutes at room temperature.
Rescue experiments
The effects of miR-24 were measured in the setting 
of overexpression of a BimL cDNA lacking the 3′UTR. 
Cells were transfected with miR-24 and with the BimL 
cDNA using Lipofectamine 2000. The effects of miR-24 
were also measured under conditions of overexpression of 
a FIH1 cDNA lacking the 3′UTR.
Luciferase assay
The 3′UTR of the human FIH1 gene was PCR-
amplified using Fw:5′GCTCTAGATGGGAAGGAGC
ATATGTCCT3′ and Rv:5′GCTCTAGATTTCAACAT
Oncotarget12www.impactjournals.com/oncotarget
GCCTCCCTCCA3′ primers cloned downstream of the 
Renilla luciferase stop codon in a pGL3 control vector 
(Promega). An inverted sequence of the miRNA-binding 
sites was used as negative control. MCF-7 cells were co-
transfected with 1.2 µg of plasmid and 400 µg of a Renilla 
luciferase expression construct, pRL-TK (Promega) with 
Lipofectamine 2000. Cells were harvested 24 h post-
transfection and analyzed with the Dual Luciferase Assay 
(Promega), according to the manufacturer’s instructions. 
The experiments were performed in triplicate.
Hypoxic culture conditions
Hypoxic conditions were achieved using a Hypoxia 
Incubator Chamber (Stem Cell Technologies, Milan, 
Italy), which generates a 1% hypoxic environment for cell 
culture. MDA-MB-231, BT-549, MCF-7 and T47D cells 
were incubated in the chamber for 6h and then harvested 
for either RNA or protein extraction.
Migration assay
Transwells Permeable Support 8.0 μm polycarbonate 
membrane 6.5 mm Insert (Corning Incorporate, Corning, 
NY, USA) were used to carry out migration assay. MDA-
MB-231 and BT-549 cells were grown as described 
above, then harvested by Trypsin-EDTA Solution (Sigma 
Aldrich, USA). 5x104 cells were washed with PBS, then 
resuspended in 1% fetal bovine serum containing RPMI 
1640 medium and seeded in the upper chamber. The lower 
chamber of the transwell was filled with 600 μl of culture 
medium containing 10% fetal bovine serum. Cells were 
incubated at 37°C for 24h. The transwells were removed 
from the 24 wells plates and stained 0.1% Crystal Violet 
in 25% methanol. Non migrated cells were scraped off 
the top of the transwell with a cotton swab. Percentage 
of migrated cells was evaluated by eluting Crystal Violet 
with 1% SDS and reading the absorbance at λ 570nm.
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